Ipsen Drug Misses Goal in Late-Stage Trial for Rare Liver Disease
Bylvay missed the study’s primary objective of showing an improvement in native liver survival rates compared to placebo.
The Source
TWSJ
Tech
It’s the Deadliest Room in the House—Especially for Seniors
TWSJ·1d ago·3 min read
Business
Is That College Scholarship Taxable? What Parents Need to Know Before Fall
TWSJ·45m ago·3 min read
Health
Novo Nordisk Seeks Injunction Against Eli Lilly in Dispute Over Weight-Loss Ads
TWSJ·27m ago·3 min read
Business
Lysol Maker Reckitt to Offload Sanctions-Hit Russian Hygiene Business
TWSJ·56m ago·3 min read
Related
On this beat
Health
Novo Nordisk Seeks Injunction Against Eli Lilly in Dispute Over Weight-Loss Ads
TWSJ·27m ago·3 min read
Health
Ipsen Drug Misses Goal in Late-Stage Trial for Rare Liver Disease
TWSJ·2h ago·3 min read
Health
Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO
TWSJ·3h ago·3 min read
Health
An outbreak of cyclosporiasis that’s sickened thousands shouldn’t prevent you from enjoying a Caesar salad—if you take the right precautions
TWSJ·21h ago·3 min read